European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver diseas
| Autor: | Benjamin Bouillet, Anne-Laure Sberna, R. Loffroy, A. Rouland, Laurence Duvillard, Jean-Michel Petit, Marie-Claude Brindisi, Bruno Vergès, T. Mouillot, A. Nguyen, Patrick Hillon, Damien Denimal |
|---|---|
| Přispěvatelé: | Lipides - Nutrition - Cancer [Dijon - U1231] ( LNC ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'Endocrinologie, Diabétologie et Maladies Métaboliques (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Proton Magnetic Resonance Spectroscopy 030209 endocrinology & metabolism Disease Type 2 diabetes Unnecessary Procedures Diabete Gastroenterology 03 medical and health sciences 0302 clinical medicine Endocrinology Fibrosis Diabetes mellitus Internal medicine Internal Medicine medicine Humans Referral and Consultation Aged Retrospective Studies FibroTest business.industry Fatty liver Middle Aged [ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism medicine.disease Obesity Diabetes Mellitus Type 2 Practice Guidelines as Topic 030211 gastroenterology & hepatology Female Steatosis business Algorithms Biomarkers Non-alcoholic fatty liver disease |
| Zdroj: | Diabetic Medicine Diabetic Medicine, Wiley, 2018, 35 (3), pp.368-375. 〈http://onlinelibrary.wiley.com/doi/10.1111/dme.13565/abstract;jsessionid=350B69C0EBD56E8D08C0E1075E28A803.f02t04〉. 〈10.1111/dme.13565〉 |
| ISSN: | 0742-3071 1464-5491 |
| DOI: | 10.1111/dme.13565/abstract;jsessionid=350B69C0EBD56E8D08C0E1075E28A803.f02t04〉. |
| Popis: | IF 3.054; International audience; AimsTo evaluate the application of the recently proposed recommendations by the European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease in people with Type 2 diabetes.MethodsA total of 179 people with Type 2 diabetes were included in this study. Liver fat content (assessed using proton magnetic resonance spectroscopy), fatty liver index score, non-alcoholic fatty liver disease fibrosis score, and SteatoTest and FibroTest scores were determined.ResultsAccording to proton magnetic resonance spectroscopy, 68.7% of participants had steatosis (liver fat content >5.5%). The application of the guidelines using several combinations (fatty liver index + non-alcoholic fatty liver disease fibrosis scores, Steatotest + FibroTest scores, proton magnetic resonance spectroscopy + non-alcoholic fatty liver disease fibrosis score, proton magnetic resonance spectroscopy + FibroTest) resulted in a referral to a liver clinic for 33.5–84.9% people with Type 2 diabetes.ConclusionsThe application of these new algorithms for the diagnosis, and follow-up of non-alcoholic fatty liver disease would lead to an excessive number of people with Type 2 diabetes being referred to a liver clinic. We suggest that new clinical and/or biological biomarkers of steatosis and fibrosis be specifically validated in people with Type 2 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text